STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3538 by analyst upside · 2026-06-27
JNJ
Johnson & Johnson
Healthcare · Market Cap $613B · P/E 29.5x
ANALYST PRICE TARGET
+1.0%
implied upside to consensus target
Current Price $254.66
Consensus Target $257.32
Bull Target $285.0
Bear Target $190.0
Analysts Covering 22
ANALYST CONSENSUS — BUY
Strong Buy
4
Buy
8
Hold
9
Sell
1
52-Week Low $151.01
52-Week High $255.05
YTD Return +24.2%
FUNDAMENTALS
Market Cap $613B
P/E Ratio (TTM) 29.5x
Forward P/E 20.0x
EPS (TTM) $8.62
PEG Ratio 3.13
Dividend Yield 2.19%
Revenue (TTM) $96.4B
Profit Margin 21.8%
52-WEEK RANGE
52-Week Low $151.01
52-Week High $255.05
Current Price $254.66
Bear Target $190.0
Bull Target $285.0
● Now $254.66 ● Target $257.32
TRADING DATA
Avg Volume 7.9M
YTD Return +24.2%
Analyst Count 22
Consensus Buy
Upside to Target +1.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Johnson & Johnson (JNJ) is currently trading at $254.66 with a Wall Street consensus price target of $257.32, implying potential upside of 1.0% over the next 12 months. 22 analysts currently cover JNJ, with a consensus rating of Buy — 55% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $285.0, while the most cautious has a target of $190.0.

JNJ operates in the Healthcare sector with a market capitalisation of $613B. The stock is up 24.2% year-to-date and is currently trading near the upper end of its 52-week range of $151.01 – $255.05.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for JNJ, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners ↑ Upgrade
Market Perform → Outperform 2026-05-13 29% win rate (7 calls)
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-04-15 Building track record
Stifel — Reiterated
Hold → Hold 2026-04-15 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2026-04-15 Building track record
Morgan Stanley — Reiterated
Overweight → Overweight 2026-04-10 Building track record
RBC Capital reit
Outperform → Outperform 2026-03-30 Building track record
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-03-19 Building track record
HSBC — Reiterated
Buy → Buy 2026-03-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →